Synthesis of IL-2 peptides and their conjugates, compositions and uses
By designing and synthesizing peptides to replace the disordered loop in IL-2, increasing IL-2Rβ binding and reducing IL-2Rα binding, the shortcomings of IL-2 peptides in terms of stability and specific binding are overcome, enabling more effective T cell and NK cell differentiation and expansion, which is suitable for immuno-oncology cell therapy.
Patent Information
- Application Number
- CN202580026229.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-01
- Filing Date
- 2025-04-01
- Publication Date
- 2026-11-17
AI Technical Summary
Existing IL-2 peptides are insufficient in terms of stability and specific binding to IL-2 receptor subunits, resulting in poor efficacy in immunotherapy, especially in promoting the expansion of regulatory T cells and affecting treatment outcomes.
We design and synthesize peptides to replace the disordered ring in IL-2, increase binding to IL-2Rβ, reduce binding to IL-2Rα, improve stability and thermal stability, and conjugate or fuse with other parts to form protein conjugates or fusion proteins for the differentiation and expansion of T cells and NK cells in vitro or in vitro.
It enhances the stability and selectivity of IL-2 peptides, reduces the expansion of regulatory T cells, maintains similar activity and phenotype, and is suitable for immuno-oncology cell therapy, providing more effective cytokine addition and function.
Smart Images

Figure CN123125225A_ABST
Abstract
Description
Technical Field
[0001] This disclosure provides for the synthesis of IL-2 polypeptides, their protein conjugates or fusion proteins, and compositions comprising them.
[0002] Cross-references to related applications
[0003] This application claims the benefit of U.S. Provisional Application No. 63 / 572,531, filed April 1, 2024, the contents of which are incorporated herein by reference in their entirety.
[0004] Sequence list declaration
[0005] The contents of the electronic sequence list titled BIOTN_42867_601_SequenceListing.xml (size: 56,722 bytes; creation date: March 28, 2025) are incorporated herein by reference in their entirety. Background Technology
[0006] Interleukins are a group of cytokine signaling molecules expressed and secreted by immune cells (e.g., leukocytes, usually lymphocytes) that regulate the activation, differentiation, proliferation, maturation, migration, and adhesion of immune cells. The function of the immune system depends primarily on interleukins, and interleukin deficiency or gene mutations are associated with autoimmune diseases or immunodeficiency.
[0007] Interleukin-2 (IL-2) promotes the proliferation, differentiation, activation, and survival of mature lymphocytes, particularly T cells. IL-2 promotes physiological antigen-specific acquired cellular immune responses and can enhance innate host defense by activating natural killer (NK) cells. IL-2 works by interacting with its α subunit (also known as IL-2Rα or CD25), β subunit (also known as IL-2Rβ or CD122), and γ subunit (also known as IL-2Rγ, γ...). c IL-2 receptors (IL-2R), including CD132, bind to control a variety of biological functions (e.g., the speed, magnitude, and duration of T-cell immune responses). Genetic defects in the IL-2 or IL-2R α or β chains can lead to immunodeficiency shortly after birth, subsequently accumulating inactive activated T cells. These phenotypic changes cannot be compensated for by other cytokines. Summary of the Invention
[0008] Embodiments of this disclosure include a synthetic polypeptide that binds to the interleukin-2 receptor subunit β (IL-2Rβ). In some embodiments, the synthetic polypeptide has less than 50% identity with SEQ ID NO: 12.
[0009] In some embodiments, the polypeptide comprises: a first domain having an amino acid sequence of LQLEHLLLDLQM (SEQ ID NO: 1); a second domain having an amino acid sequence of RDLISNINVI (SEQ ID NO: 2), EDLISNINVI (SEQ ID NO: 3), RDTISNINVI (SEQ ID NO: 4), RDLIENINVI (SEQ ID NO: 5), RDTIENINV (SEQ ID NO: 6), EDLIENINVI (SEQ ID NO: 7), EDTISNINV (SEQ ID NO: 8), or EDTIENINV (SEQ ID NO: 9); and a third domain having an amino acid sequence of LNRWITFCQ (SEQ ID NO: 10) or LNRWITFAQ (SEQ ID NO: 11).
[0010] In some embodiments, the first, second, and third domains may be present in the synthetic polypeptide in any order from the N-terminus to the C-terminus. In some embodiments, the order of the first, second, and third domains in the synthetic polypeptide from the N-terminus to the C-terminus is: first-second-third or first-third-second. In some embodiments, each domain is separated by a spacer polypeptide. In some embodiments, each spacer polypeptide is individually 10 to 60 amino acids in length.
[0011] In some embodiments, the synthetic polypeptide contains one or more additional amino acids at the N-terminus and C-terminus of the first, second, and third structural domains.
[0012] In some embodiments, the synthetic polypeptide comprises: a first domain having an amino acid sequence of LQLEHLLLDLQM (SEQ ID NO: 1); a second domain having an amino acid sequence of RDLISNINVI (SEQ ID NO: 2); and a third domain having an amino acid sequence of LNRWITFCQ (SEQ ID NO: 10).
[0013] In some embodiments, the synthetic polypeptide comprises an amino acid sequence having at least 70% identity with one of SEQ ID NO: 13-26. In some embodiments, the synthetic polypeptide comprises an amino acid sequence of any of SEQ ID NO: 13-26.
[0014] In some embodiments, the synthetic polypeptide comprises at least one of EDLISNINVI (SEQ ID NO: 3), RDTISNINVI (SEQ ID NO: 4), RDLIENINVI (SEQ ID NO: 5), RDTIENINV (SEQ ID NO: 6), EDLIENINVI (SEQ ID NO: 7), EDTISNINV (SEQ ID NO: 8), and EDTIENINV (SEQ ID NO: 9).
[0015] In some embodiments, the synthetic polypeptide comprises one or more amino acid substitutions compared to SEQ ID NO: 18. In some embodiments, the one or more amino acid substitutions compared to SEQ ID NO: 18 include substitutions of C34, E83, R86, L88, S90, and combinations thereof. In some embodiments, the one or more amino acid substitutions compared to SEQ ID NO: 18 include C34A, E83K, R86E, L88T, S90E, and combinations thereof. In some embodiments, the one or more amino acid substitutions compared to SEQ ID NO: 18 further include at least one additional amino acid substitution.
[0016] In some embodiments, the synthetic polypeptide comprises an amino acid sequence having at least 70% identity with one of SEQ ID NO: 27-33. In some embodiments, the synthetic polypeptide comprises an amino acid sequence of any of SEQ ID NO: 27-33.
[0017] In some implementations, the synthetic polypeptide is 90 to 130 amino acids in length.
[0018] In some implementations, the synthetic peptide is thermally stable.
[0019] In some implementations, the synthetic peptide exhibits increased stability in cell culture media compared to recombinant human IL-2.
[0020] In some implementations, the synthetic peptide has a completely or partially reduced binding to the interleukin-2 receptor subunit α (IL-2Rα) compared to recombinant human IL-2.
[0021] Further embodiments of this disclosure include protein conjugates or fusion proteins comprising a synthetic polypeptide as disclosed herein linked to at least one portion. In some embodiments, the at least one portion is a protein, protein domain, polypeptide, or peptide. In some embodiments, the at least one portion comprises an antibody or a fragment thereof. In some embodiments, the at least one portion is polyethylene glycol (PEG).
[0022] Other embodiments of this disclosure include compositions comprising synthetic peptides, protein conjugates, or fusion proteins as disclosed herein, and a carrier. In some embodiments, the composition is a cell culture medium or a component thereof.
[0023] Further embodiments of this disclosure include methods for differentiating, stimulating, and / or expanding T cells or NK cells in vitro or in vitro. In some embodiments, these methods include contacting T cells, NK cells, or their precursor or progenitor cells with synthetic peptides, protein conjugates, or fusion proteins, or compositions as disclosed herein.
[0024] Other aspects and implementations of this disclosure will become apparent from the following detailed description. Attached Figure Description
[0025] Figure 1A-1B : Figure 1A The structures of IL-2 (black) and its receptors α (bottom left), β (left), and γ (top) are shown from a protein database (ID: 2B5I). This overlaps with the exemplary synthetic AlphaFold structure (white). Figure 1B It shows the relationship with Figure 1A The same structure, but with the receptor removed to better visualize the differences in IL-2. The synthetic IL-2 structure maintains the helix that interacts with β and γ receptors; however, the disordered loop adjacent to the α receptor in IL-2 is replaced by the helix in synthetic IL-2.
[0026] Figure 2 The initial synthetic IL-2 peptides were screened by binding the extracellular domain of IL-2Rβ to an Avi tag and staining with a streptavidin fluorophore, followed by flow cytometry measurement of mean fluorescence intensity (MFI). This was performed in two experiments, separated in the figure by recombinant human interleukin-2 (rhIL-2). MFI was interpreted as a reading of binding affinity.
[0027] Figure 3 Synthetic IL-2 peptides with high IL-2Rβ binding and high expression in *E. coli* were selected to test binding data for all three receptors (IL-2Rα, IL-2Rβ, and IL-2Rγ). Binding was measured by adding a recombinant form of the extracellular domain of each receptor to an Avi tag, staining with a streptavidin fluorophore, and reading by flow cytometry. MFI is the reading of binding affinity.
[0028] Figure 4Surface plasmon resonance (SPR) measurements were performed on the synthesized IL-2 constructs. Compared to rhIL-2 (455 nM), the KRβ of the synthesized IL-2 variant was reduced. D The dissociation constant is much stronger, except for ABG6-M3.
[0029] Figure 5 STAT5 phosphorylation staining in YT cells (a malignant hematopoietic cell line mimicking NK cells). STAT5 phosphorylation is a measure of IL-2 signaling. YT cells with and without CD25 expression (IL2Rα) were stained with an antibody targeting STAT5 phosphorylation. rhIL-2 showed the strongest phosphorylation when cells expressed CD25; however, staining for synthetic IL-2 (ABG6-M1) did not change when CD25 was knocked out.
[0030] Figure 6 NK92 proliferation data. NK92 exhibits reduced CD25 expression, and its proliferation is IL-2-dependent. The first figure shows NK92 proliferation after 4 days of culture. The second figure includes an IL-2Rα blocking antibody to separate the effects of IL-2Rβ and IL-2Rγ. Column C indicates the EC50 of ABG6-M2, which exhibits the strongest activity.
[0031] Figure 7 Measurement of IL-2 stimulation and INF-γ secretion in NK92 cells. Column C is ED50, and column D is the maximum response. Both synthetic IL-2s stimulated more INF-γ secretion than rhIL-2 stimulation.
[0032] Figure 8 CD4 and CD8 positive human T cells isolated by stimulation with CD3 / CD28 Dynabeads and IL-2. ABG6-M1 cells showed a similar fold increase as rhIL-2.
[0033] Figure 9 CD8-positive human T cells isolated by stimulation with CD3 / CD28 Dynabeads and IL-2. ABG6-M1 showed a slightly increased amplification relative to rhIL-2, which may be due to the lower CD25 expression of CD8+ T cells.
[0034] Figure 10 Day 12 T cell phenotype. Synthetic IL-2 showed phenotypic equivalence compared to rhIL-2. CM: Central memory CD45RA-CCR7+, initial ( ): CD45RA+CCR7+, TEMRA: CD45RA+CCR7- terminally differentiated effector memory cells, EM: effector memory CD45RA-CCR7- cells.
[0035] Figure 11 Comparison of the solubility of rhIL-2 and synthetic IL-2 (ABG6-M1) when expressed in BL21 DE3 E. coli. Protein was harvested from lysed cells after IPGT (+) induction. Total protein was aliquoted and aggregates were separated from soluble fractions by centrifugation. Most rhIL-2 was insoluble, as indicated by a band at 14.5 kDa in the aggregate lanes, while most synthetic IL2 was present in the soluble fraction (band at 10 kDa).
[0036] Figure 12A and 12B Example of the stability of synthesized IL-2 (ABG6-M1) and rhIL-2 in cell culture medium. ABG6-M1 and rIL-2 were incubated in DMEM medium at 37°C for 10 days at various concentrations. Figure 12A Or incubate at 10 ng / mL for 10 days, 1 month, and 2 months. Figure 12B The activity was assessed by a proliferation bioassay in NK92 cells. The specific activity % of the control was determined using a control containing rIL-2 stored at 4°C without any incubation. Detailed Implementation
[0037] This article discloses synthetic IL-2 peptides, their protein conjugates or fusion proteins, and compositions comprising them. These synthetic IL-2 peptides lack the disordered ring found in wild-type (WT) IL-2 and exhibit increased stability and expression. One consequence of replacing the disordered ring in IL-2 is the loss of IL-2Rα binding; however, because the synthetic peptides have increased IL-2Rβ binding, they maintain similar activity and phenotype compared to recombinant human interleukin-2 (rhIL-2) with a cysteine-to-serine mutation at position 125 of WT IL-2. Furthermore, the low IL-2Rα binding has the advantage of favoring cells with low IL-2Rα expression, which has potential benefit in immuno-oncology cell therapy as these cells do not support Treg cell expansion. For example, regulatory T cells express high IL-2Rα and therefore expand less proportionally with the disclosed synthetic IL-2 peptides, which may be desirable for some results. The synthetic IL-2 peptides are also thermostable. The extended shelf life of synthetic IL-2 peptides facilitates automated cytokine addition in cell cultures and enhances their function in closed cell culture systems. In contrast, WT IL-2 requires freezing to achieve stability.
[0038] The chapter titles used in this section and all publicly available content in this document are for organizational purposes only and are not intended to be restrictive.
[0039] definition
[0040] Unless otherwise defined herein, scientific and technical terms used in conjunction with this disclosure shall have the meanings commonly understood by one of ordinary skill in the art. For example, any terms and techniques described herein in conjunction with cell and tissue culture, molecular biology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization are those well-known and commonly used in the art. The meaning and scope of terms should be clear; however, in the event of any potential ambiguity, the definitions provided herein shall prevail over any dictionary or external definition. Furthermore, unless the context requires otherwise, singular terms shall include plural forms and plural terms shall include singular forms.
[0041] The terms “comprising,” “including,” “having,” “has,” “may,” “contain,” and variations thereof, as used herein, are intended as open-ended transitional phrases, terms, or words that do not exclude the possibility of additional behaviors or structures. As used herein, comprising a sequence or a SEQ ID NO generally means that at least one copy of said sequence is present in said peptide or polynucleotide. However, two or more copies are also contemplated. Unless explicitly specified otherwise in the context, the singular forms “an” and “the” include plural referents. This disclosure also contemplates other embodiments “comprising the embodiments or elements presented herein,” “consisting of the embodiments or elements presented herein,” and “consisting substantially of the embodiments or elements presented herein,” whether explicitly stated or not.
[0042] In describing the numerical ranges in this article, each intermediate value with the same precision is explicitly considered. For example, for the range 6–9, the numbers 7 and 8 are considered in addition to 6 and 9, and for the range 6.0–7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly considered.
[0043] As used herein, the term "antibody" refers to a protein naturally produced by the immune system to identify and neutralize foreign objects, such as bacteria and viruses. Typically, an antibody is a protein containing at least one complementarity-determining region (CDR). The CDR forms the "hypervariate region" of the antibody responsible for antigen binding (discussed further below). A complete antibody typically consists of four polypeptides: two identical copies of the heavy (H) chain polypeptide and two identical copies of the light (L) chain polypeptide. Each heavy chain contains an N-terminal variable (V) terminator. H ) region and three C-terminal constants (C H1 C H2 and C H3 The light chain contains an N-terminal variable (V) region, and each light chain contains an N-terminal variable (V) region. L) region and a C-terminal constant (C L The light chains of an antibody can be designated as either κ (κ) or lambda (λ) based on the amino acid sequence of their constant domains. In a typical antibody, each light chain is linked to the heavy chain by a disulfide bond, and the two heavy chains are linked to each other by disulfide bonds. The variable regions of the light chains are aligned with the variable regions of the heavy chains, and the constant regions of the light chains are aligned with the first constant region of the heavy chains. The remaining constant regions of the heavy chains are aligned with each other.
[0044] The variable regions of each pair of light and heavy chains form the antigen-binding sites of antibodies. VH and VL The regions have the same overall structure, and each region contains four frame regions (FW or FR). As used herein, the term "frame region" refers to a relatively conserved amino acid sequence located between CDRs within the variable region. Each variable domain has four frame regions, which are designated as FR1, FR2, FR3, and FR4. The frame regions form β-sheets that provide the structural framework of the variable region (see, for example, CA Janeway et al. (edited)). Immunobiology , 5th edition, Garland Publishing, New York, NY (2001)).
[0045] The frame region is connected by three CDRs. As discussed above, the three CDRs (designated CDR1, CDR2, and CDR3) form the “hypervariant region” of the antibody responsible for antigen binding. The CDRs form loops that connect to the β-sheet structure formed by the frame region and, in some cases, constitute part of the β-sheet structure formed by the frame region. While the constant regions of the light and heavy chains do not directly participate in antibody-antigen binding, they can influence the orientation of the variable region. The constant regions also exhibit various effector functions, such as participating in antibody-dependent complement-mediated cleavage or antibody-dependent cytotoxicity via interactions with effector molecules and cells.
[0046] As used herein, when an antibody or other entity (e.g., an antigen-binding domain) “specifically recognizes” or “specifically binds” to an antigen or epitope, the antibody or other entity preferentially recognizes the antigen in a complex mixture of proteins and / or macromolecules and binds the antigen or epitope with a significantly higher affinity than other entities that do not exhibit the antigen or epitope. In this respect, “significantly higher affinity” means that the affinity is high enough to enable the detection of an antigen or epitope different from the entity using the desired assay or measurement device. Typically, it means having at least 10 6 M -1 (For example, >10) 6 M -1 >10 7 M -1>10 8 M -1 >10 9 M -1 >10 10 M -1 >10 11 M -1 >10 12 M -1 >10 13 M -1 The binding constant (K) of (etc.) a The binding affinity of the antibody to the specific epitope. In some such embodiments, the antibody can bind to different antigens, as long as those different antigens contain the specific epitope. For example, in some cases, homologous proteins from different species may contain the same epitope.
[0047] Therefore, as used herein, antibody refers to monoclonal antibody; monospecific antibody (e.g., which may be monoclonal or may be produced by means other than from common germ cells); multispecific antibody; human antibody; humanized antibody (fully or partially humanized); animal antibody, such as, but not limited to, poultry (e.g., ducks or geese), sharks, whales, and mammals (including non-primates (e.g., cattle, pigs, camels, llamas, horses, goats, rabbits, sheep, hamsters, guinea pigs, cats, dogs, rats, mice, etc.) or non-human primates (e.g., monkeys, chimpanzees, etc.)); recombinant antibody; chimeric antibody; single-chain Fv (“scFv”); single-chain antibody; single-domain antibody; anti-idiotype (“anti-Id”) antibody; dual-domain antibody; dual-variable-domain (DVD) or triple-variable-domain (TVD) antibody (dual-variable-domain immunoglobulins and their preparation methods are described in Wu, C. et al., Nature Biotechnology , 25(11):1290-1297 (2007) and PCT international application WO2001 / 058956, the contents of which are incorporated herein by reference); or domain antibodies (dAbs) (e.g., such as those in Holt et al., Trends in Biotechnology As described in 21:484-490 (2014), and includes naturally occurring single-domain antibodies (sdAbs), such as those found in cartilaginous fish and camelids, or synthetic ones, such as nanobodies, VHHs, or other domain structures, as well as functionally active epitope-binding fragments of any of the above. Antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass.
[0048] The terms “fragment of antibody,” “antibody fragment,” and “antigen-binding fragment of antibody” are used interchangeably herein to refer to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (see generally Holliger et al.). Nat. Biotech ., 23 (9): 1126-1129 (2005)). Any antigen-binding fragment of the antibody described herein is within the scope of this disclosure. Antibody fragments are intended to contain, for example, one or more CDRs, variable regions (or portions thereof), constant regions (or portions thereof), or combinations thereof. Examples of antibody fragments include, but are not limited to: (i) Fab fragments, which are formed by V L V H C L and C H1 (ii) The F(ab')2 fragment, which is a bivalent fragment consisting of two Fab fragments connected by a disulfide bridge at the hinge region, and (iii) the Fv fragment, which consists of the V of the antibody single arm. L and V H The domains consist of: (iv) the Fab' fragment, which is formed by breaking the disulfide bridge of the F(ab')2 fragment using mild reducing conditions; (v) the disulfide-stabilized Fv fragment (dsFv); and (vi) the domain antibody (dAb), which is an antibody monovariable domain (V) that specifically binds to the antigen. H or V L Polypeptide.
[0049] A “humanized” form of a non-human (e.g., rodent) antibody is a chimeric antibody containing a minimal sequence derived from a non-human antibody. In most cases, a humanized antibody is a human immunoglobulin (receptor antibody) in which residues of the receptor hypervariable region are replaced by residues of the hypervariable region of a non-human species (donor antibody) (such as a mouse, rat, rabbit, or non-human primate) with the desired antibody specificity, affinity, and capability. In some cases, the framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may contain residues not found in the receptor or donor antibody. These modifications are performed to further refine antibody performance. Typically, a humanized antibody will contain at least one of substantially all and usually two variable domains, wherein all or substantially all of the hypervariable loops correspond to those of the non-human immunoglobulin, and all or substantially all of the FRs are those of the human immunoglobulin sequence. The humanized antibody will optionally also contain at least a portion of the immunoglobulin constant region (Fc), typically a portion of the immunoglobulin constant region (Fc) of a human immunoglobulin. For further details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).
[0050] As used herein, the term "monoclonal antibody" refers to an antibody produced by a single clone of B lymphocytes that targets a single epitope on an antigen. Monoclonal antibodies are typically produced using hybridoma technology, as described by Köhler and Milstein. Eur. J. Immunol ., 5 First described in 511-519 (1976). Monoclonal antibodies can also be produced using recombinant DNA methods (see, for example, U.S. Patent 4,816,567) or isolated from phage display antibody libraries (see, for example, Clackson et al.). Nature , 352 : 624--628 (1991)); and Marks et al., J. Mol. Biol ., 222 :581--597 (1991)) or produced by transgenic mice carrying the fully human immunoglobulin system (see, for example, Lonberg, Nat. Biotechnol ., 23 (9): 1117-25 (2005), and Lonberg, Handb. Exp. Pharmacol ., 181: 69-97 (2008)). In contrast, "polyclonal" antibodies are antibodies secreted by different B cell lineages in an animal. Polyclonal antibodies are a collection of immunoglobulin molecules that recognize multiple epitopes on the same antigen.
[0051] As used herein, the term “monospecific” antibody refers to an antibody having one or more binding sites, each of which binds to the same epitope of the same antigen.
[0052] As used herein, a “conjugate” refers to two or more parts or molecules connected to each other by covalent or non-covalent interactions. More specifically, the term “protein conjugate” refers to a protein or polypeptide that has been modified by the addition of another part or molecule (e.g., another peptide, protein, or polypeptide).
[0053] As used herein, the term "contact" means to bring into contact, to be in contact, or to enter into a state of contact. As used herein, "contact" means a state or condition of touching or directly or partially approaching. Contacting the composition with the target can be done in any manner known to those skilled in the art.
[0054] As used herein, the term "ex vivo" refers to cells that have been removed from a living organism (e.g., a human) and multiplied outside the organism (e.g., in a petri dish, test tube, or bioreactor).
[0055] When used in connection with proteins, genes, nucleic acids, or polynucleotides in cells or organisms, the term "exogenous" means that the protein, gene, nucleic acid, or polynucleotide has been artificially introduced into the cell or organism, or, when used in connection with cells, that the cell has been isolated and subsequently artificially introduced into other cells or organisms. Exogenous nucleic acids may originate from different organisms or cells, or they may be one or more additional copies of nucleic acids naturally present in an organism or cell. Exogenous cells may originate from different organisms, or they may originate from the same organism.
[0056] As used herein, “nucleic acid” and “nucleic acid sequence” refer to polymers or oligomers of pyrimidine and / or purine bases (preferably cytosine, thymine, and uracil, and adenine and guanine, respectively) (see Albert L. Lehninger, Principles of Biochemistry, pp. 793-800 (Worth Pub. 1982)). This technique considers any deoxyribonucleotide, ribonucleotide, or peptide nucleic acid component and any chemical variant thereof, such as methylated, hydroxymethylated, or glycosylated forms of these bases. Polymers or oligomers may be heterogeneous or homogeneous in composition and may be isolated from naturally occurring sources or produced artificially or synthetically. Furthermore, nucleic acids may be DNA or RNA or mixtures thereof and may exist permanently or transitionally in single-stranded or double-stranded forms (including homoduplex, heteroduplex, and hybrid states). In some implementations, the nucleic acid or nucleic acid sequence contains other types of nucleic acid structures, such as, for example, DNA / RNA helices, peptide nucleic acids (PNAs), morpholinonucleotides (see, for example, Braasch and Corey, Biochemistry, 41(14): 4503-4510 (2002) and U.S. Patent No. 5,034,506), locked nucleic acids (LNAs; see Wahllestedt et al., Proc. Natl. Acad. Sci. USA, 97: 5633-5638 (2000)), cyclohexenyl nucleic acids (see Wang, J. Am. Chem. Soc., 122: 8595-8602 (2000)) and / or ribozymes. Therefore, the term "nucleic acid" or "nucleic acid sequence" may also encompass chains containing non-natural nucleotides, modified nucleotides, and / or non-nucleotide components (e.g., "nucleotide analogs") that exhibit the same function as natural nucleotides; furthermore, as used herein, the term "nucleic acid sequence" refers to oligonucleotides, nucleotides, or polynucleotides, as well as fragments or portions thereof, and DNA or RNA of genomic or synthetic origin, which may be single-stranded or double-stranded, and represents a sense strand or antisense strand. The terms "nucleic acid," "polynucleotide," "nucleotide sequence," and "oligonucleotide" are used interchangeably. They refer to polymeric forms of nucleotides (deoxyribonucleotides or ribonucleotides, or their analogs) of any length.
[0057] A peptide or polypeptide is a linked sequence of two or more amino acids connected by peptide bonds. Polypeptides can be natural, synthetic, or a combination of natural and synthetic modifications. Peptides or polypeptides can be modified by adding sugars, lipids, or other portions not included in the amino acid chain. The terms "polypeptide," "oligopeptide," "protein," and "peptide" are used interchangeably herein. The peptide can be produced by recombinant genetic techniques or chemical synthesis. Peptides can be isolated and purified by any number of standard methods (including, but not limited to, differential solubility (e.g., precipitation), centrifugation, chromatography (e.g., affinity, ion exchange, and size exclusion)) or by any other standard technique known in the art.
[0058] As used herein, the term "amino acid" or "any amino acid" refers to any and all amino acids, including naturally occurring amino acids (e.g., α-amino acids), non-natural amino acids, modified amino acids, and non-natural amino acids. It includes both D-amino acids and L-amino acids. Natural amino acids include those found in nature, such as the 23 amino acids that bind together to form numerous protein building blocks. These are primarily L-stereomers, although some D-amino acids are present in bacterial envelopes and some antibiotics. "Non-standard" natural amino acids include, for example, pyrrolidone (found in methanogens and other eukaryotes), selenocysteine (found in many non-eukaryotes and most eukaryotes), and valine (found in Bacillus subtilis). Bacillus subtilis The antifungal peptide contains N-formylmethionine (encoded by the start codon AUG in bacteria, mitochondria, and chloroplasts). "Unnatural" or "non-natural" amino acids are non-proteinogenic amino acids (e.g., amino acids not naturally encoded or found in the genetic code) that are either naturally occurring or chemically synthesized. More than 140 non-natural amino acids are known, and there are likely thousands more combinations. Examples of "non-natural" amino acids include β-amino acids (β... 3 and β 2The list includes homoamino acids, proline and pyruvate derivatives, 3-substituted alanine derivatives, glycine derivatives, cyclic-substituted phenylalanine and tyrosine derivatives, linear core amino acids, diamino acids, D-amino acids, α-methyl amino acids, and N-methyl amino acids. Non-natural or unnatural amino acids also include modified amino acids. "Modified" amino acids include those that have been chemically modified to include groups, multiple groups, or chemical moieties not naturally present on the amino acid (e.g., natural amino acids). According to some embodiments, peptide inhibitors comprise an intramolecular bond between two amino acid residues present in the peptide inhibitor. It should be understood that the amino acid residues forming the bond undergo some changes when bound to each other compared to when unbound. Referring to a specific amino acid means including both unbound and bound amino acids. For example, when involved in the intramolecular bond according to the invention, the unbound amino acid residue homoserine (hSer) may take the form of 2-aminobutyric acid (Abu).
[0059] In most cases, the names of naturally occurring and non-natural aminoacyl residues used herein follow the naming conventions recommended by the IUPAC Commission on the Nomenclature of Organic Chemistry and the IUPAC-IUB Commission on Biochemical Nomenclature, as set forth in "Nomenclature of α-Amino Acids (Recommendations, 1974)" Biochemistry, 14(2), (1975). If the names and abbreviations of amino acids and aminoacyl residues used in this specification and the appended claims differ from these recommendations, this will be clearly stated to the reader.
[0060] In this specification, unless naturally occurring amino acids are referred to by their full names (e.g., alanine, arginine, etc.), they are represented by their conventional three-letter or one-letter abbreviations (e.g., Ala or A for alanine, Arg or R for arginine, etc.). The term "L-amino acid" as used herein refers to the "L" isomer of the peptide, while the term "D-amino acid" refers to the "D" isomer of the peptide (e.g., Dphe, (D)Phe, D-Phe, or...). D F represents the D isomer of phenylalanine. The amino acid residues in the D isomer can substitute for any L-amino acid residue, as long as the peptide retains the desired function.
[0061] For less common or non-naturally occurring amino acids, unless mentioned by their full name (e.g., sarcosine, ornithine, etc.), their residues are usually represented by three- or four-letter codes, including Sar or Sarc (sarcosine, i.e., N-methylglycine), Aib (α-aminoisobutyric acid), Dab (2,4-diaminobutyric acid), Dapa (2,3-diaminopropionic acid), γ-Glu (γ-glutamic acid), Gaba (γ-aminobutyric acid), β-Pro (pyrrolidine-3-carboxylic acid) and 8Ado (8-amino-3,6-dioxanoic acid), Abu (2-aminobutyric acid), βhPro (β-homoproline), βhPhe (β-homophenylalanine), and Bip (β,β-diphenylalanine), as well as Ida (iminodiacetic acid).
[0062] As used herein, the term "sequence identity percentage" or "identity percentage" refers to the percentage of amino acids in an amino acid sequence that are identical to the corresponding amino acids in a reference sequence after aligning two sequences and, where necessary, introducing gaps to achieve the maximum identity percentage. Many mathematical algorithms are known for obtaining optimal alignments and calculating identity between two or more sequences, and are incorporated into numerous available software programs. Examples of such programs include CLUSTAL-W, T-Coffee, and ALIGN (for nucleic acid and amino acid sequence alignment), BLAST programs (e.g., BLAST2.1, BL2SEQ, and subsequent versions), and FASTA programs (e.g., FASTA3x, FAS™, and SSEARCH) (for sequence alignment and sequence similarity search). Sequence alignment algorithms are also disclosed in, for example, Altschul et al., J. Molecular Biol., 215(3): 403-410 (1990); Beigert et al., Proc. Natl. Acad. Sci. USA, 106(10):3770-3775 (2009); Durbin et al. (ed.), Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids, Cambridge University Press, Cambridge, UK (2009); Soding, Bioinformatics, 21(7): 951-960 (2005); Altschul et al., Nucleic Acids Res., 25(17): 3389-3402 (1997); and Gusfield, Algorithms on Strings, Trees and Sequences, Cambridge University Press, Cambridge UK (1997)).
[0063] The terms “non-naturally occurring,” “engineered,” and “synthetic” are used interchangeably and indicate human involvement. When referring to a macromolecule (e.g., a nucleic acid molecule or polypeptide), the term means that the macromolecule is at least substantially free of at least one other component naturally associated with it and found in nature, and / or that the macromolecule is associated with at least one other component not naturally associated with it in nature, and / or that there are one or more variations, such as nucleic acid or amino acid sequences, compared to such sequences found in nature.
[0064] "Subject" can be human or non-human and can include, for example, animal strains or species used as a "model system" for research purposes, such as mouse models. Similarly, subjects can include adults or adolescents (e.g., children). Furthermore, "subject" can refer to any living organism, preferably a mammal (e.g., human and non-human). Examples of mammals include, but are not limited to, any member of the mammal class: humans, non-human primates such as chimpanzees and other ape and monkey species; farm animals such as cattle, horses, sheep, goats, and pigs; domesticated animals such as rabbits, dogs, and cats; and laboratory animals including rodents such as rats, mice, and guinea pigs. Examples of non-mammals include, but are not limited to, birds, fish, etc.
[0065] While similar or equivalent methods and materials to those described herein may be used in the practice or testing of this disclosure, preferred methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated herein by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and are not intended to be limiting.
[0066] Synthetic peptides
[0067] This article discloses a synthetic polypeptide that binds to the interleukin-2 receptor subunit β (IL-2Rβ). The synthetic polypeptide comprises a first domain, a second domain, and a third domain, which are arranged in any order along the length of the synthetic polypeptide and optionally separated by spacer polypeptides.
[0068] In some embodiments, the amino acid sequence of the nuclease lacks significant identity or significant amino acid homology with wild-type IL-2 (SEQ ID NO: 12) or recombinant interleukin-2 products (e.g., SEQ ID NO: 34). Therefore, the synthetic polypeptide does not contain the amino acid sequence of SEQ ID NO: 12 or 34. For example, the synthetic polypeptide may include less than 50% (e.g., less than 45%, less than 40%, less than 35%, less than 30%, less than 25%, or less than 20%) sequence identity with SEQ ID NO: 12.
[0069] In some embodiments, the synthetic polypeptide comprises a first domain having the amino acid sequence LQLEHLLLDLQM (SEQ ID NO: 1) or an amino acid sequence having one, two, or three amino acid substitutions compared to SEQ ID NO: 1. In some embodiments, the synthetic polypeptide comprises a second domain having the amino acid sequence RDLISNINVI (SEQ ID NO: 2), EDLISNINVI (SEQ ID NO: 3), RDTISNINVI (SEQ ID NO: 4), RDLIENINVI (SEQ ID NO: 5), RDTIENINV (SEQ ID NO: 6), EDLIENINVI (SEQ ID NO: 7), EDTISNINV (SEQ ID NO: 8), or EDTIENINV (SEQ ID NO: 9), or an amino acid sequence having one or two amino acid substitutions compared to any of SEQ ID NO: 2-9. For example, in some embodiments, the arginine at position 1 in any of SEQ ID NO: 2 or 4-6 is substituted with another amino acid. In some embodiments, arginine at position 1 of any of SEQ ID NO: 2 or 4-6 is replaced by a positively charged amino acid (e.g., glutamic acid, aspartic acid). In some embodiments, serine at position 5 of any of SEQ ID NO: 2-4 and 8 is replaced by another amino acid. In some embodiments, serine at position 5 of any of SEQ ID NO: 2-4 and 8 is replaced by a positively charged amino acid (e.g., glutamic acid, aspartic acid). In some embodiments, leucine at position 3 of any of SEQ ID NO: 2, 3, 5 and 6 is replaced by another amino acid. In some embodiments, leucine at position 3 of any of SEQ ID NO: 2, 3, 5 and 6 is replaced by an uncharged amino acid (e.g., glycine, alanine, valine, leucine, isoleucine, methionine, serine, threonine).
[0070] In some embodiments, the synthetic polypeptide comprises a second domain having the amino acid sequence of LNRWITFCQ (SEQ ID NO: 10) or LNRWITFAQ (SEQ ID NO: 11), or an amino acid sequence having one or two amino acid substitutions compared to either SEQ ID NO: 10 or 11. For example, in some embodiments, the cysteine at position 8 of SEQ ID NO: 10 is substituted with another amino acid. In some embodiments, the cysteine at position 8 of SEQ ID NO: 10 is substituted with an uncharged amino acid (e.g., glycine, alanine, valine, leucine, isoleucine, methionine, serine, threonine).
[0071] In some embodiments, the synthetic polypeptide comprises a first domain having the amino acid sequence LQLEHLLLDLQM (SEQ ID NO: 1), or an amino acid sequence having one, two, or three amino acid substitutions compared to SEQ ID NO: 1; a second domain having the amino acid sequence RDLISNINVI (SEQ ID NO: 2), or an amino acid sequence having one or two amino acid substitutions compared to SEQ ID NO: 2; and a third domain having the amino acid sequence LNRWITFCQ (SEQ ID NO: 10), or an amino acid sequence having one or two amino acid substitutions compared to SEQ ID NO: 10.
[0072] In some embodiments, the synthetic polypeptide comprises a first domain having an amino acid sequence of LQLEHLLLDLQM (SEQ ID NO: 1); a second domain having an amino acid sequence of RDLISNINVI (SEQ ID NO: 2); and a third domain having an amino acid sequence of LNRWITFCQ (SEQ ID NO: 10).
[0073] In some embodiments, the synthetic polypeptide comprises a first domain having the amino acid sequence LQLEHLLLDLQM (SEQ ID NO: 1), or an amino acid sequence having one, two, or three amino acid substitutions compared to SEQ ID NO: 1; a second domain having the amino acid sequence EDLISNINVI (SEQ ID NO: 3), RDTISNINVI (SEQ ID NO: 4), RDLIENINVI (SEQ ID NO: 5), RDTIENINV (SEQ ID NO: 6), EDLIENINVI (SEQ ID NO: 7), EDTISNINV (SEQ ID NO: 8), or EDTIENINV (SEQ ID NO: 9), or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 3-9; and a third domain having LNRWITFCQ (SEQ ID NO: 10) or LNRWITFAQ (SEQ ID NO: 10). 11) of the amino acid sequence, or having one or two substituted amino acid sequences compared to either SEQ ID NO: 10 or 11.
[0074] In some embodiments, the synthetic polypeptide comprises a first domain having the amino acid sequence LQLEHLLLDLQM (SEQ ID NO: 1) or an amino acid sequence having one, two, or three amino acid substitutions compared to SEQ ID NO: 1, and a third domain having the amino acid sequence LNRWITFAQ (SEQ ID NO: 11) or an amino acid sequence having one or two amino acid substitutions compared to SEQ ID NO: 11. In selected embodiments, the synthetic polypeptide comprises a first domain having the amino acid sequence LQLEHLLLDLQM (SEQ ID NO: 1) and a third domain having the amino acid sequence LNRWITFAQ (SEQ ID NO: 11).
[0075] In some embodiments, the synthetic polypeptide comprises a first domain having the amino acid sequence LQLEHLLLDLQM (SEQ ID NO: 1), or an amino acid sequence having one, two, or three amino acid substitutions compared to SEQ ID NO: 1; a second domain having the amino acid sequence EDLIENINVI (SEQ ID NO: 7), or an amino acid sequence having one or two amino acid substitutions compared to SEQ ID NO: 7; and a third domain having the amino acid sequence LNRWITFAQ (SEQ ID NO: 11), or an amino acid sequence having one or two amino acid substitutions compared to SEQ ID NO: 11.
[0076] In a selected embodiment, the synthetic polypeptide comprises a first domain having an amino acid sequence of LQLEHLLLDLQM (SEQ ID NO: 1); a second domain having an amino acid sequence of EDLIENINVI (SEQ ID NO: 7); and a third domain having an amino acid sequence of LNRWITFAQ (SEQ ID NO: 11).
[0077] In some embodiments, the synthetic polypeptide comprises a first domain having the amino acid sequence LQLEHLLLDLQM (SEQ ID NO: 1), or an amino acid sequence having one, two, or three amino acid substitutions compared to SEQ ID NO: 1; a second domain having the amino acid sequence RDTIENINV (SEQ ID NO: 6), or an amino acid sequence having one or two amino acid substitutions compared to SEQ ID NO: 6; and a third domain having the amino acid sequence LNRWITFAQ (SEQ ID NO: 11), or an amino acid sequence having one or two amino acid substitutions compared to SEQ ID NO: 11.
[0078] In a selected embodiment, the synthetic polypeptide comprises a first domain having an amino acid sequence of LQLEHLLLDLQM (SEQ ID NO: 1); a second domain having an amino acid sequence of RDTIENINV (SEQ ID NO: 6); and a third domain having an amino acid sequence of LNRWITFAQ (SEQ ID NO: 11).
[0079] In some embodiments, the synthetic polypeptide comprises a first domain having the amino acid sequence LQLEHLLLDLQM (SEQ ID NO: 1), or an amino acid sequence having one, two, or three amino acid substitutions compared to SEQ ID NO: 1; a second domain having the amino acid sequence EDTIENINV (SEQ ID NO: 9), or an amino acid sequence having one or two amino acid substitutions compared to SEQ ID NO: 9; and a third domain having the amino acid sequence LNRWITFAQ (SEQ ID NO: 11), or an amino acid sequence having one or two amino acid substitutions compared to SEQ ID NO: 11.
[0080] In a selected embodiment, the synthetic polypeptide comprises a first domain having an amino acid sequence of LQLEHLLLDLQM (SEQ ID NO: 1); a second domain having an amino acid sequence of EDTIENINV (SEQ ID NO: 9); and a third domain having an amino acid sequence of LNRWITFAQ (SEQ ID NO: 11).
[0081] The first, second, and third domains can be arranged in a specific order along the length of the synthetic polypeptide. In some embodiments, the first domain is located at the N-terminus of the first, second, and third domains. In some embodiments, the second domain is located at the C-terminus of the first, second, and third domains. In some embodiments, the third domain is located at the C-terminus of the first, second, and third domains. In some embodiments, the order of the first, second, and third domains in the synthetic polypeptide from the N-terminus to the C-terminus is first-second-third. In some embodiments, the order of the first, second, and third domains in the synthetic polypeptide from the N-terminus to the C-terminus is first-third-second.
[0082] In some embodiments, each of the first, second, and third domains is separated by a spacer polypeptide. The spacer polypeptide contains an amino acid sequence of such length and identity that the synthetic polypeptide can be adapted to a conformation in which the first, second, and third domains are substantially arranged in a helical structure that interacts with IL-2Rβ, such as... Figure 1A and 1B As shown.
[0083] In some embodiments, each spacer polypeptide is individually 10 to 60 amino acids long. In some embodiments, the synthetic polypeptide comprises a spacer polypeptide of 10 to 20 amino acids long and a second spacer polypeptide of 30 to 60 amino acids long. For example, the spacer polypeptide between the first and second domains may be 10 to 20 amino acids long, while the spacer polypeptide between the second and third domains may be 30 to 60 amino acids long. In some embodiments, each spacer polypeptide individually comprises an amino acid sequence having at least 70% identity with any of SEQ ID NO: 35-61. In some embodiments, each spacer polypeptide individually comprises an amino acid sequence of any of SEQ ID NO: 35-61.
[0084] In some embodiments, the synthetic polypeptide comprises one or more additional amino acids at the N-terminus and C-terminus of the first, second, and third domains. Therefore, the synthetic polypeptide may comprise one or more additional amino acids from the N-terminus to the far N-terminus of the first, second, and third domains, and / or one or more additional amino acids from the C-terminus to the far C-terminus of the first, second, and third domains. In some embodiments, the synthetic polypeptide comprises 1 to 10 amino acids from the N-terminus to the far N-terminus of the first, second, and third domains. In some embodiments, the synthetic polypeptide comprises more than 10 amino acids from the N-terminus to the far N-terminus of the first, second, and third domains. In some embodiments, the synthetic polypeptide comprises 1 to 10 amino acids from the C-terminus to the far C-terminus of the first, second, and third domains. In some embodiments, the synthetic polypeptide comprises more than 10 amino acids from the C-terminus to the far C-terminus of the first, second, and third domains.
[0085] In some embodiments, the synthetic polypeptide comprises an amino acid sequence having at least 70% identity with one of SEQ ID NO: 13-26. In some embodiments, the synthetic polypeptide comprises the amino acid sequences of SEQ ID NO: 13-26.
[0086] In some embodiments, the synthetic polypeptide comprises one or more amino acid substitutions compared to SEQ ID NO: 18. In some embodiments, compared to SEQ ID NO: 14, the one or more amino acid substitutions are located at positions C34, E83, R86, L88, S90, and combinations thereof. In some embodiments, compared to SEQ ID NO: 18, the one or more amino acid substitutions further include at least one additional amino acid substitution.
[0087] In some embodiments, the substitution of one or more amino acids includes substitutions at positions R86 and S90. In some embodiments, the substitution of one or more amino acids includes substitutions at positions C34, R86, and S90.
[0088] In some embodiments, the substitution of one or more amino acids includes substitutions at positions L88 and S90. In some embodiments, the substitution of one or more amino acids includes substitutions at positions C34, L88, and S90.
[0089] In some embodiments, the substitution of one or more amino acids includes substitutions at positions C34, R86, L88, and S90.
[0090] In some embodiments, compared to SEQ ID NO: 18, the one or more amino acid substitutions include C34A, E83K, R86E, L88T, S90E, and combinations thereof. In some embodiments, the one or more amino acid substitutions include R86E and S90E. In some embodiments, the one or more amino acid substitutions include C34A, R86E, and S90E. In some embodiments, the one or more amino acid substitutions include substitutions at positions L88T and S90E. In some embodiments, the one or more amino acid substitutions include substitutions at positions C34A, L88T, and S90E. In some embodiments, the one or more amino acid substitutions include substitutions at positions C34A, R86E, L88T, and S90E.
[0091] In some embodiments, the synthetic polypeptide comprises an amino acid sequence having at least 70% identity with one of SEQ ID NO: 27-33. In some embodiments, the synthetic polypeptide comprises the amino acid sequences of SEQ ID NO: 27-33.
[0092] Synthetic peptides may be permitted to use methods as described above and Figure 1A and 1B The synthetic polypeptide may be of any length as described herein and necessary to promote increased stability, purification yield, and other properties, as well as the exemplary polypeptides disclosed in SEQ ID NO: 13-33. In some embodiments, the synthetic polypeptide is 90 to 130 amino acids in length. The synthetic polypeptide may be 90 to 100, 90 to 110, 90 to 120, 100 to 110, 100 to 120, 100 to 130, 110 to 120, 110 to 130, or 120 to 130 amino acids.
[0093] Compared to rhIL-2, synthetic peptides may exhibit increased stability and expression. In some embodiments, the synthetic peptide is thermostable. A “thermally stable” peptide is one that retains increased activity relative to a reference peptide under certain conditions, such as certain temperatures and / or for a certain duration, or maintains activity at elevated temperatures compared to native, lower temperature conditions. In some embodiments, the synthetic peptide retains the structure / conformation necessary for full or near-full activity after elevated temperatures for a period of time (e.g., about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes). In some embodiments, the synthetic peptide has increased thermal stability compared to rhIL-2. Therefore, after exposure to high heat conditions for the same duration, the synthetic peptide may retain higher activity than rhIL-2, the synthetic peptide may retain activity at higher temperatures compared to rhIL-2, and / or the synthetic peptide may retain activity at any given high temperature for an increased duration compared to rhIL-2.
[0094] Synthetic peptides exhibit stability in cell culture media. Therefore, synthetic peptides can exhibit increased activity retention in cell culture media for a period of time at any temperature. Synthetic peptides can exhibit increased activity retention in cell culture media under conditions suitable for use in cell culture (e.g., temperature, CO2 concentration, presence of other cell culture components and / or cells) and at concentrations suitable for the proposed use. In some embodiments, synthetic peptides exhibit increased stability in cell culture media compared to rhIL-2. Synthetic peptides retain higher activity than rhIL-2 after the same period of exposure to cell culture conditions, maintain activity at lower concentrations in cell culture media compared to rhIL-2, and / or maintain activity in cell culture media for an increased duration compared to rhIL-2.
[0095] The synthetic peptide may have reduced binding to the interleukin-2 receptor subunit α (IL-2Rα). In some embodiments, the synthetic peptide does not bind to IL-2Rα; for example, the synthetic peptide exhibits a binding character similar to or reduced from a negative control known to not bind to IL-2Rα. In some embodiments, the synthetic peptide has a reduced binding character to IL-2Rα compared to rhIL-2. In some embodiments, the binding character of the synthetic peptide to IL-2Rα is reduced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to rhIL-2.
[0096] Compared to the mutations specifically considered and disclosed herein, any synthetic polypeptide described herein may contain one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25) additional amino acid substitutions. In some embodiments, the synthetic polypeptide described herein may contain one or more amino acid substitutions outside the first, second, and third domains.
[0097] Amino acid "substitution" or "replacement" refers to the substitution of one amino acid at a given position or residue within a polypeptide sequence by another amino acid at the same position or residue. Amino acids are broadly classified as either "aromatic" or "aliphatic." Aromatic amino acids include aromatic rings. Examples of "aromatic" amino acids include histidine (H or His), phenylalanine (F or Phe), tyrosine (Y or Tyr), and tryptophan (W or Trp). Non-aromatic amino acids are broadly classified as "aliphatic." Examples of "aliphatic" amino acids include glycine (G or Gly), alanine (A or Ala), valine (V or Val), leucine (L or Leu), isoleucine (I or Ile), methionine (M or Met), serine (S or Ser), threonine (T or Thr), cysteine (C or Cys), proline (P or Pro), glutamic acid (E or Glu), aspartic acid (D or Asp), asparagine (N or Asn), glutamine (Q or Gln), lysine (K or Lys), and arginine (R or Arg).
[0098] Amino acid substitutions or replacements can be conserved, semi-conserved, or non-conserved. The phrase “conservative amino acid substitution” or “conservative mutation” refers to the replacement of one amino acid with another that shares a common characteristic. A functional approach to defining the common characteristic between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins in homologous organisms (Schulz and Schirmer, Principles of Protein Structure, Springer-Verlag, New York (1979)). Based on such analysis, amino acid groups can be defined where amino acids within a group preferentially exchange with each other and are therefore most similar to each other in their effect on the overall protein structure (Schulz and Schirmer, ibid.). Examples of conserved amino acid substitutions include amino acid substitutions within the aforementioned subgroups, such as lysine replacing arginine and vice versa, to maintain a positive charge; glutamic acid replacing aspartic acid and vice versa, to maintain a negative charge; serine replacing threonine, to maintain a free -OH group; and glutamine replacing asparagine, to maintain a free -NH2 group. "Semi-conserved mutations" include amino acid substitutions within the same group but not the same subgroup listed above. For example, substitutions of aspartic acid for asparagine or asparagine for lysine involve amino acids in the same group but different subgroups. "Non-conserved mutations" involve amino acid substitutions between different groups (e.g., lysine for tryptophan or phenylalanine for serine, etc.).
[0099] In some embodiments, the synthetic polypeptide is covalently or non-covalently linked to at least one moiety. Therefore, protein conjugates comprising the synthetic polypeptide as described herein and at least one moiety are also provided herein. For example, the synthetic polypeptide may be fused to a moiety that provides labeling or visualization (e.g., GFP). The synthetic polypeptide may be fused to a moiety having another function or activity that can be used to target certain cells (e.g., a therapeutic agent, an antibody). The synthetic polypeptide may be fused to a moiety that provides increased efficacy to the synthetic polypeptide (e.g., a half-life-extending moiety). The synthetic polypeptide may be fused to a moiety that masks the function of the synthetic polypeptide except under certain conditions or at certain locations (e.g., an inactivating domain). For example, the synthetic polypeptide may be linked to polyethylene glycol (PEG) molecules, albumin, the Fc region or domain of a protein of interest, the antigen-binding domain of an antibody, an antibody that targets a certain cell or blocks unwanted activity or interaction, a toxin, NKG2D, etc.
[0100] The synthetic peptide can be linked to this moiety using standard chemical conjugation techniques. Methods for the chemical conjugation of peptides are known in the art. Common conjugation strategies are typically based on side-chain modifications of lysine or cysteine. Non-canonical amino acids can facilitate the introduction of chemical orthogonal handles at predefined sites in a given protein sequence, such as for oxime linkages or click chemistry methods. Furthermore, a wide variety of methods can be used for site-specific protein modifications with varying degrees of generality. Exemplary chemical linker systems include, but are not limited to, carbodiimide (EDC), thiol-maleimide, succinimide 3-(2-pyridyldithio)propionate (SPDP), and periodate systems.
[0101] In addition to chemical strategies, enzymatic conjugation may be suitable because it allows for highly controlled modification of proteins (e.g., antibodies) via specific peptide tags. Exemplary enzymatic processes include, but are not limited to, sortase ligation, subtiligase-catalyzed ligation, phosphopantetheinyl transferase, tyrosinase, and transglutaminase. Components of a protein conjugate may include additional parts or linkers (e.g., amino acids) to which the substrate is attached for the enzymatic reaction, provided that the enzymatic reaction can proceed. Thus, protein conjugates may retain additional parts or linkers to separate the components.
[0102] When the part is a protein, protein domain, polypeptide, peptide, etc., protein conjugates can also be produced as continuous proteins (e.g., fusion proteins) using genetic engineering techniques.
[0103] The fusion protein is not limited by the orientation or directionality of the synthetic polypeptide and the at least one part. For example, any single part can be fused to the N-terminus or C-terminus of the synthetic polypeptide in any orientation (e.g., N-terminus to N-terminus, C-terminus to C-terminus, N-terminus to C-terminus, or C-terminus to N-terminus) directly or indirectly (e.g., fused to another part fused to the synthetic polypeptide).
[0104] Synthetic peptides can be partially fused via linker peptides. Linker peptides can have any of a variety of amino acid sequences. Proteins can be linked by spacer peptides, which are typically flexible, but other chemical bonds are not excluded. Suitable linkers include peptides with lengths between 4 and 40 amino acids or between 4 and 25 amino acids. These linkers can be generated by coupling proteins using synthetic oligonucleotides encoding the linker, or they can be encoded by nucleic acid sequences encoding fusion proteins. Peptide linkers with a degree of flexibility can be used. Linker peptides can have virtually any amino acid sequence, but it is preferable that the linker has a sequence that produces a typically flexible peptide. The use of small amino acids such as glycine and alanine is useful in forming flexible peptides. The creation of such sequences is routine for those skilled in the art. A variety of different linkers are commercially available and considered suitable for use, including, but not limited to, glycine-serine polymers, glycine-alanine polymers, and alanine-serine polymers.
[0105] Any synthetic peptide or fusion protein may also include a localization or signaling sequence, a sequence tag (e.g., a tag for detection, purification, and / or monitoring of expression), a protein transduction domain sequence, or a combination thereof. In some embodiments, the synthetic peptide or fusion protein may include an epitope tag (e.g., a 3xFLAG tag, an HA tag, a Myc tag, etc.). The localization or signaling sequence, sequence tag, and protein transduction domain sequence may be located at the N-terminus, C-terminus, or a combination thereof of the respective synthetic peptide or fusion protein and may be linked to an adapter peptide.
[0106] Nucleic acid
[0107] This document also discloses nucleic acids encoding synthetic polypeptides or their protein conjugates or fusion proteins as described herein. Nucleic acids can be DNA, RNA, or combinations thereof. In some embodiments, the nucleic acid comprises one or more vectors.
[0108] In some implementations, nucleic acids are engineered for codon optimization. It should be understood that changing codons to those most frequently used in the cells or subjects of interest allows for maximum expression. Such modified nucleic acid sequences are generally described in the art as "codon-optimized." In some implementations, a nucleic acid sequence is considered codon-optimized if at least about 60% (e.g., about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 98%) of the codons encoded in the nucleic acid sequence are preferred codons for the subject of interest.
[0109] This disclosure also provides DNA segments encoding the synthetic polypeptides or their protein conjugates or fusion proteins disclosed herein, vectors containing such segments, and cells containing such vectors. Vectors can be used to propagate DNA segments in suitable cells and / or to allow expression from the segments (e.g., expression vectors). Those skilled in the art will recognize various vectors that can be used for the propagation and expression of nucleic acid sequences.
[0110] This disclosure also provides engineered, non-naturally occurring vectors and vector systems that can encode synthetic polypeptides or their protein conjugates or fusion proteins as disclosed herein. The vectors can be introduced into cells capable of expressing the polypeptides they encode, including any suitable prokaryotic or eukaryotic cells.
[0111] Viral and non-viral gene transfer methods can be used to introduce nucleic acids encoding components of the systems of the present invention into cells. Such methods can be used to apply nucleic acids encoding components of the systems of the present invention to cells in cultures. Non-viral vector delivery systems include DNA plasmids, granules, RNA (e.g., transcripts of vectors described herein), nucleic acids, and nucleic acids complexed with a delivery medium. Viral vector delivery systems include DNA and RNA viruses that have an appended or integrated genome upon delivery to cells. Viral vectors include, for example, retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, and herpes simplex virus vectors.
[0112] In some implementations, non-replicating plasmids or plasmids that can be solidified at high temperatures can be used, allowing the removal of any or all synthetic polypeptides or their protein conjugates or fusion proteins from the cell under certain conditions. For example, this could allow DNA integration by transforming bacteria of interest, leaving behind engineered strains that do not have the memory of the plasmid or vector used for integration.
[0113] A drug selection strategy can be employed by positively selecting cells that have undergone DNA integration. Donor nucleic acids may contain one or more drug-selectable markers within the cargo. Then, assuming the original donor plasmid has been removed, drug selection can be used to enrich integrated clones. Colony screening can be used to isolate clonal events.
[0114] A variety of viral constructs can be used to deliver synthetic peptides or their protein conjugates or fusion proteins, or combinations thereof, to target cells. Non-limiting examples of such recombinant viruses include recombinant adeno-associated virus (AAV), recombinant adenovirus, recombinant lentivirus, recombinant retrovirus, recombinant herpes simplex virus, recombinant poxvirus, bacteriophage, etc. This disclosure provides vectors, such as retroviruses or lentiviruses, capable of integrating into the host genome. See, for example, Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989; Kay, MA et al., 2001 Nat. Medic. 7(1):33-40; and Walther W. and Stein U., 2000 Drugs, 60(2):249-71, which are incorporated herein by reference.
[0115] In one embodiment, a DNA segment encoding a synthetic polypeptide or its protein conjugate or fusion protein is contained in a plasmid vector that allows for the expression and subsequent isolation and purification of one or more proteins generated by the recombinant vector. Therefore, the proteins disclosed herein can be purified after expression, obtained through chemical synthesis, or obtained through recombinant methods.
[0116] To construct cells expressing synthetic peptides or their protein conjugates or fusion proteins, expression vectors for stable or transient expression can be constructed and introduced into cells using conventional methods as described herein. For example, nucleic acids encoding synthetic peptides or their protein conjugates or fusion proteins can be cloned into suitable expression vectors (such as plasmids or viral vectors operatively linked to a suitable promoter). The choice of expression vector / plasmid / viral vector should be suitable for integration and replication in eukaryotic cells.
[0117] In some embodiments, the vector of this disclosure can drive the expression of one or more sequences in prokaryotic cells. Usable promoters include the T7 RNA polymerase promoter, constitutive E. coli promoters, and promoters that are widely recognized by transcriptional mechanisms in a wide range of bacterial organisms. This system can be used with a variety of bacterial hosts.
[0118] In some embodiments, the vectors of this disclosure can be used to drive the expression of one or more sequences in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, Nature (1987) 329:840, which is incorporated herein by reference) and pMT2PC (Kaufman et al., EMBO J. (1987) 6:187, which is incorporated herein by reference). When used in mammalian cells, the control function of the expression vector is typically provided by one or more regulatory elements. For example, commonly used promoters are derived from polyomaviruses, adenovirus 2, cytomegalovirus, simian virus 40, and other viruses disclosed herein and known in the art. For other suitable expression systems for prokaryotic and eukaryotic cells, see, for example, Chapters 16 and 17 of Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL., 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, which is incorporated herein by reference.
[0119] The vectors disclosed herein may comprise any of a number of promoters known in the art, wherein the promoter is constitutive, regulatory or inducible, cell type specific, tissue specific or species specific. In addition to sequences sufficient to guide transcription, the promoter sequences of the present invention may also include sequences of other regulatory elements involved in regulating transcription (e.g., enhancers, Kozak sequences and introns). Many promoter / regulatory sequences that can be used to drive constitutive expression of genes are available in the art, including but not limited to, CMV (cytomegalovirus promoter), EF1a (human elongation factor 1α promoter), SV40 (simian vacuolating virus 40 promoter), PGK (mammalian phosphoglycerate kinase promoter), Ubc (human ubiquitin C promoter), human β-actin promoter, rodent β-actin promoter, CBh (chicken β-actin promoter), CAG (hybrid promoter containing CMV enhancer, chicken β-actin promoter and rabbit β-globin splice acceptor), TRE (tetracycline response element promoter), H1 (human polymerase III RNA promoter), U6 (human U6 small nucleus promoter), etc. Other promoters that can be used to express components of the system of the present invention include, but are not limited to, cytomegalovirus (CMV) intermediate early promoters, viral LTRs such as Rous sarcoma virus LTR, HIV-LTR, HTLV-1 LTR, Moloney murine leukemia virus (MMLV) LTR, myeloproliferative sarcoma virus (MPSV) LTR, spleen focal formation virus (SFFV) LTR, simian virus 40 (SV40) early promoter, herpes simplex virus TK virus promoter, and extension factor 1-α (EF1-α) promoters with or without EF1-α introns. Other promoters include any constitutively active promoter. Alternatively, any regulatory promoter can be used such that its expression can be regulated intracellularly.
[0120] Furthermore, inducible and tissue-specific expression can be achieved by placing the nucleic acid encoding such a molecule under the control of an inducible or tissue-specific promoter / regulatory sequence. Examples of tissue-specific or inducible promoter / regulatory sequences that can be used for this purpose include, but are not limited to, the rhodopsin promoter, the MMTV LTR inducible promoter, the SV40 late enhancer / promoter, the synaptic 1 promoter, the ET hepatocyte promoter, the GS glutamine synthase promoter, and many other promoters. Additionally, promoters well known in the art that can be induced in response to inducing agents such as metals, glucocorticoids, tetracyclines, hormones, etc., are also contemplated for use in this invention. Therefore, it should be understood that this disclosure includes any promoter / regulatory sequence capable of driving the expression of a desired protein operatively linked thereto.
[0121] The vectors disclosed herein can direct the expression of nucleic acids in specific cell types (e.g., using tissue-specific regulatory elements for nucleic acid expression). Such regulatory elements include promoters that can be tissue-specific or cell-specific. When applied to promoters, the term "tissue-specific" refers to a promoter that directs the selective expression of a nucleotide sequence of interest to a specific type of tissue (e.g., a seed) when the same nucleotide sequence of interest is not expressed in different types of tissues. Similarly, the term "cell-type-specific" when applied to promoters refers to a promoter that directs the selective expression of a nucleotide sequence of interest in a specific type of cell when the same nucleotide sequence of interest is not expressed in different types of cells within the same tissue. When applied to promoters, the term "cell-type-specific" also means a promoter that promotes the selective expression of a nucleotide sequence of interest in a region within a single tissue. The cell-type specificity of a promoter can be assessed using methods well-known in the art, such as immunohistochemical staining.
[0122] Additionally, the vector may contain some or all of the following: selection marker genes, such as the neomycin gene for selecting stable or transient transfectants in host cells; enhancer / promoter sequences from immediate early genes from human CMV for high-level transcription; transcription termination and RNA processing signals from SV40 for mRNA stability; 5'- and 3'-untranslated regions for mRNA stability and translation efficiency from highly expressed genes such as α-globin or β-globin; SV40 polyomavirus origin of replication and ColE1 for appropriate appendage replication; internal ribosome binding sites (IRES), universal multiple cloning sites; T7 and SP6 RNA promoters for in vitro transcription of sense and antisense RNA; "suicide switches" or "suicide genes" that, when triggered, lead to cell death of the vector-carrying cell (e.g., HSV thymidine kinase, inducible caspases such as iCasp9); and reporter genes for assessing chimeric receptor expression. Suitable vectors and methods for generating vectors containing transgenes are well known and available in the art. Selection markers also include chloramphenicol resistance, tetracycline resistance, spectinomycin resistance, streptomycin resistance, erythromycin resistance, rifampin resistance, bleomycin resistance, heat-adapted kanamycin resistance, gentamicin resistance, hygromycin resistance, trimethoprim resistance, dihydrofolate reductase (DHFR), and GPT; *Saccharomyces cerevisiae* (Saccharomyces cerevisiae) S. cerevisiae The URA3, HIS4, LEU2 and TRP1 genes.
[0123] When introduced into a cell, the vector can remain an autonomously replicating sequence or an extrachromosomal element, or it can integrate into the host DNA.
[0124] Vectors according to this disclosure can be transformed, transfected, or otherwise introduced into a variety of cells. Transfection refers to the uptake of a vector by cells, regardless of whether any coding sequence is actually expressed. Many transfection methods are known to those skilled in the art, such as lipofectamine, calcium phosphate coprecipitation, electroporation, DEAE-dextran treatment, microinjection, viral infection, and other methods known in the art. Transduction refers to the entry of a virus into a cell and the expression (e.g., transcription and / or translation) of a sequence delivered by the viral vector genome. In the context of recombinant vectors, "transduction" generally refers to the entry of a recombinant viral vector into a cell and the expression of a nucleic acid of interest delivered by the vector genome.
[0125] Any vector containing a nucleic acid sequence encoding a synthetic polypeptide or its protein conjugate or fusion protein is also within the scope of this disclosure. Such vectors can be delivered into host cells by suitable methods. Methods for delivering vectors into cells are well known in the art and may include DNA or RNA electroporation; transfection reagents for delivering DNA or RNA such as liposomes or nanoparticles; delivery of DNA, RNA, or proteins by mechanical deformation (see, for example, Sharei et al., Proc. Natl. Acad. Sci. USA 110(6): 2082-2087 (2013), which is incorporated herein by reference); or viral transduction. Nucleic acids may be delivered as part of a larger construct, such as a plasmid or viral vector, or directly, for example by electroporation, lipid vesicles, viral transporters, microinjection, and biolistics (high-speed particle bombardment). Similarly, constructs containing one or more transgenes may be delivered by any method suitable for introducing nucleic acids into cells. In some embodiments, the nucleic acid of the construct or encoding a component of the system of the present invention is a DNA molecule. In some embodiments, the nucleic acid encoding a component of the system of the present invention is a DNA vector and can be electroporated into cells. In some embodiments, the nucleic acid encoding a component of the system of the present invention is an RNA molecule that can be electroporated into cells.
[0126] Additionally, delivery media such as nanoparticle- and lipid-based mRNA or protein delivery systems can be used. Other examples of delivery media include lentiviral vectors, ribonucleoprotein (RNP) complexes, lipid-based delivery systems, gene guns, hydrodynamics, electroporation or nuclear transfection microinjection, and bioballistics. Various gene delivery methods are discussed in detail by Nayerossadat et al. (Adv Biomed Res. 2012; 1: 27) and Ibraheem et al. (Int J Pharm. 2014 Jan 1; 459(1-2):70-83) (these are incorporated herein by reference).
[0127] Composition
[0128] This document also discloses compositions comprising a synthetic polypeptide or a protein conjugate or fusion protein thereof as described herein, or a nucleic acid molecule containing a sequence encoding a synthetic polypeptide or a protein conjugate or fusion protein thereof.
[0129] In some embodiments, the composition is a cell culture medium. A cell culture medium is any culture medium containing nutrients that maintain cell viability and support proliferation, used for culturing cells. A cell culture medium may contain any of the following substances in a suitable combination: one or more salts, one or more buffers, amino acids, glucose or other sugars, antibiotics, serum or serum substitutes, and other components such as peptide growth factors.
[0130] The composition may also contain excipients or pharmaceutically acceptable carriers. The selection of excipients or pharmaceutically acceptable carriers depends on a variety of factors, including but not limited to the specific route of administration, the effect of the excipients on solubility and stability, and the nature of the dosage form.
[0131] Excipients and carriers may include any and all solvents, dispersion media, antibacterial and antifungal agents, isotonic agents, and absorption delay agents. Some examples of materials that can be used as excipients and / or carriers are sugars, including but not limited to lactose, glucose, and sucrose; starches, including but not limited to corn starch and potato starch; cellulose and its derivatives, including but not limited to sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth gum; malt; gelatin; talc; excipients including but not limited to cocoa butter and suppository waxes; oils, including but not limited to peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; ethylene glycol; including propylene glycol; esters, including but not limited to ethyl oleate and ethyl laurate; agar; buffers, including but not limited to magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol and phosphate buffer solutions; and other non-toxic, compatible lubricants, including but not limited to sodium dodecyl sulfate and magnesium stearate, as well as colorants, release agents, preservatives, and antioxidants. The compositions and methods of preparation of the present invention will be readily apparent to those skilled in the art. The techniques and formulations can be found, for example, in Remington's Pharmaceutical Sciences, 19th edition (Mack Publishing Company, 1995).
[0132] These compositions may also contain buffers (e.g., neutral buffered saline or phosphate buffered saline); carbohydrates (e.g., glucose, mannose, sucrose or dextran); mannitol; antioxidants; antibacterial agents; chelating agents (such as EDTA or glutathione); solutes that make the formulation isotonic, hypotonic or weakly hypertonic with the recipient's blood; suspending agents; thickeners; and / or preservatives (typically present in protein compositions).
[0133] The disclosed synthetic polypeptides or their protein conjugates or fusion proteins may be encapsulated, alone or as a group, in microcapsules (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), macroemulsions, or sustained-release formulations. The disclosed compositions or components may be in liposomes and combined with amphiphilic agents (such as lipids) present in aqueous solutions in aggregated forms such as micelles, insoluble monolayers, liquid crystals, or lamellar layers. Suitable lipids for liposome formulations include, but are not limited to, monoglycerides, diglycerides, thioglycosides, lysophosphatidylcholine, phospholipids, saponins, and bile acids. The preparation of such liposome formulations is within the scope of the art.
[0134] The disclosed compositions or their components may be prepared individually or as a group in a hydrogel. The term "hydrogel" as used herein refers to a specific type of gel in which a water-swellable polymer matrix can absorb a large amount of water within a macromolecular three-dimensional network bound together by covalent or non-covalent crosslinking.
[0135] method
[0136] This disclosure also provides methods for differentiating, stimulating, and / or expanding immune cells (e.g., T cells, NK cells, and B cells) in vitro or in vitro. The methods described herein can be used to generate immune cells with commercial or clinical applications.
[0137] "Differentiation" refers to the process by which cells differentiate from one cell type (e.g., multipotent, totipotent, or pluripotent differentiateable cells) into another cell type, such as a target differentiated cell (e.g., T cells). Typically, as a result of differentiation, cell potency or proliferation decreases, or cells migrate to a more developmentally restricted state. "Proliferation" refers to increased cell division, i.e., symmetrical or asymmetrical cell division. "Expansion" refers to an increase in the number of cells compared to their initial number, for example, as a result of cell division and cell death. "Stimulation" or "activation" refers to inducing a change in the biological state of cells (e.g., T cells and NK cells), which can lead to the expression of activation markers; the production of cytokines; and increased autophagy, proliferation, and / or cytotoxicity to target cells.
[0138] These methods involve contacting immune cells (e.g., T cells, NK cells) or their precursor or progenitor cells with synthetic polypeptides, their protein conjugates or fusion proteins, or compositions containing them, as described herein.
[0139] In some embodiments, these methods include adding a synthetic polypeptide, its protein conjugate, or fusion protein, or a composition comprising them, to a buffer or cell culture medium containing immune cells (e.g., T cells, NK cells) or their precursor or progenitor cells. Alternatively or additionally, in some embodiments, these methods include adding a buffer or cell culture medium containing a synthetic polypeptide or its protein conjugate or fusion protein to an immune cell population (e.g., cells under culture conditions). Therefore, buffers or cell culture media containing synthetic polypeptides as disclosed herein, their protein conjugates or fusion proteins, are also disclosed herein.
[0140] Apparatus used for contacting and subsequently culturing immune cells (e.g., T cells, NK cells) or their precursor or progenitor cells may include, but is not particularly limited to: flasks, tissue culture flasks, petri dishes, culture dishes, tissue culture dishes, multiplex culture dishes, microplates, microplates, multiwell plates, microslides, chamber slides, tubes, trays, CellSTACK® chambers, Grex® culture dishes, culture bags, and roller flasks, as long as they are capable of culturing cells in them. Depending on the culture requirements, cells may be cultured in any volume (e.g., at least or about 0.2, 0.5, 1, 2, 5, 10, 20, 30, 40, 50 ml, 100 ml, 150 ml, 200 ml, 250 ml, 300 ml, 350 ml, 400 ml, 450 ml, 500 ml, 550 ml, 600 ml, 800 ml, 1000 ml, 1500 ml, or any range derived therefrom). A vessel can be a bioreactor, which can refer to any device or system that supports a biologically active environment. A vessel can be part of an open system or a closed system. The duration of incubation, as well as other components of the cell culture medium and cell culture conditions (e.g., temperature, CO2), are those that promote cell growth and allow the desired degree of differentiation, stimulation, and / or expansion.
[0141] In some implementations, these methods also include contacting immune cells (e.g., T cells, NK cells) or their precursor or progenitor cells with one or more additional cytokines. Cytokines may include, but are not limited to, FLT3 ligand (FLT3L), interleukin-7 (IL-7), stem cell factor (SCF), thrombopoietin (TPO), IL-4, IL-6, IL-15, IL-21, TNF-α, TGF-β, interferon-γ, interferon-λ, TSLP, thymopentin, pleiotropic growth factor, and metaphase I factor.
[0142] In some embodiments, these methods further include stimulating immune cells with one or more stimulants to generate an activated population of immune cells under suitable conditions. Any combination of one or more stimulants may be used to generate an activated population of cells, including, but not limited to, antibodies or functional fragments thereof targeting T cell stimulating or co-stimulating molecules (e.g., anti-CD2 antibodies, anti-CD3 antibodies, anti-CD28 antibodies, or functional fragments thereof); or any other suitable mitogen (e.g., tetradecanoylphorbol acetate (TPA), phytohemagglutinin (PHA), concanavalin A (conA), lipopolysaccharide (LPS), pokeweed mitogen (PWM)); or natural ligands of stimulating or co-stimulating molecules.
[0143] As used herein, the terms "T cell" or "T lymphocyte" refer to cells that express CD3 (CD3+). + ) and T cell receptor (TCR) + T cells are cells that express various T cells. T cells include thymocytes, naive T lymphocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, or activated T lymphocytes. T cells can be T helper (Th) cells, such as T helper 1 (Th1) or T helper 2 (Th2) cells. T cells can be helper T cells (HTL; CD4+ T cells), CD4+ T cells, cytotoxic T cells (CTL; CD8+ T cells), tumor-infiltrating cytotoxic T cells (TIL; CD8+ T cells), CD4+CD8+ T cells, or any other T cell subset. Other illustrative T cell populations suitable for use include naive T cells and memory T cells. "NKT cells" are also covered, which are specialized T cell populations that express semi-invariant αβ T cell receptors but also express multiple molecular markers commonly associated with NK cells, such as NK1.1. NKT cells include NK1.1+ and NK1.1-, as well as CD4+, CD4-, CD8+, and CD8- cells. It also includes "γ-δ T cells (γδ T cells)," a small subset of T cells whose surface has different TCRs composed of γ and δ chains instead of α- and β-TCR chains. It also includes "regulatory T cells" or "Tregs," which refer to T cells that suppress abnormal or excessive immune responses and play a role in immune tolerance. Treg cells are typically Foxp3-positive CD4+ T cells, but can also include Foxp3-negative regulatory T cells, which are IL-10-producing CD4+ T cells.
[0144] T cells can be any type of T cell, such as cultured T cells, like primary T cells, or T cells derived from cultured T cell lines, such as Jurkat, SupT1, etc., or T cells obtained from a subject (e.g., a mammal). If obtained from a subject, T cells can be obtained from many sources, including but not limited to bone marrow, blood, lymph nodes, thymus, or other tissues or fluids. T cells can also be enriched or purified. T cells can be human T cells. T cells can be T cells isolated from humans. T cells can be any type of T cell and can be at any developmental stage, including but not limited to CD4+ / CD8+ double-positive T cells, CD8+ T cells (e.g., cytotoxic T cells), CD4+ helper T cells, such as Th1 and Th2 cells, peripheral blood mononuclear cells (PBMCs), peripheral blood leukocytes (PBLs), tumor-infiltrating cells, memory T cells, naive T cells, etc. T cells can be CD8+ T cells or CD4+ T cells.
[0145] T cells may be genetically engineered T cells. In some embodiments, the genetically engineered T cells may be genetically engineered before and / or after the disclosed methods. In some embodiments, the T cells express a chimeric antigen receptor (CAR) or an engineered / exogenous T cell receptor. CARs and engineered TCRs can confer arbitrary specificity to immune effector cells. In some embodiments, the T cells have been genetically engineered to knock out endogenous receptors or other molecules that affect the function of the cell of interest (e.g., knocking out undesired functions to confer increased safety or efficacy to the engineered cells). In some embodiments, these methods also include genetically engineering the T cells.
[0146] Natural killer (NK) cells are differentiated lymphocytes. NK cells are characterized by their ability to bind to and kill cells that do not express their own MHC / HLA antigens by activating specific cell-lysing enzymes, to kill tumor cells or other diseased cells expressing ligands of the NK activation receptor, and to release protein molecules called cytokines that stimulate or suppress immune responses. Like T cells, NK cells can be cultured NK cells, such as primary NK cells, or NK cells derived from cultured cell lines, or NK cells obtained from a subject, and can be genetically engineered. In some implementations, these methods also include genetically engineering the NK cells.
[0147] Precursor cells or progenitor cells are less differentiated or undifferentiated cells with the potential to differentiate into cell types of interest (e.g., T cells, NK cells). Depending on cell differentiation, precursor cells can be pluripotent, multipotent, and totipotent, while progenitor cells can be unipotent or oligopotent. Precursor cells or progenitor cells include stem cells (e.g., embryonic stem cells (ESCs), adult stem cells (ASCs), induced pluripotent stem cells (iPSCs)) and cells that are more differentiated and specialized than stem cells (e.g., progeny of stem cells).
[0148] In some implementations, stem cells or progenitor cells may be selected from embryonic stem cells, hematopoietic stem cells or progenitor cells, cells isolated from bone marrow, umbilical cord blood, peripheral blood, thymus, or the progenitor cells may have already differentiated in vitro from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs). Stem cells or progenitor cells as used herein may be, but are not limited to, ESCs, induced pluripotent stem cells, or tissue stem cells (also known as tissue-specific stem cells or somatic stem cells). Stem cells or progenitor cells derived from primary tissues or ESCs or iPSCs may be derived from humans or non-human animals (e.g., mice).
[0149] Embryonic stem (ES) cells are pluripotent stem cells derived from early embryos. Tissue stem cells exist in specific locations within tissues and possess undifferentiated intracellular structures. Therefore, tissue stem cells typically have low pluripotency. Based on their site of origin, such as the dermal system, digestive system, bone marrow system, and nervous system, tissue stem cells are classified into various categories. Tissue stem cells in the bone marrow system include hematopoietic stem cells and mesenchymal stem cells.
[0150] Hematopoietic stem cells or progenitor cells are cells that are classified as hematopoietic lineages but are capable of further hematopoietic differentiation. They include hematopoietic stem cells, pluripotent hematopoietic stem cells (hematopoietic cells), bone marrow progenitor cells, megakaryocyte progenitor cells, erythrocyte progenitor cells, and lymphoid progenitor cells. Hematopoietic stem cells (HSCs) are pluripotent stem cells that produce all types of blood cells, including bone marrow (monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes / platelets, dendritic cells) and lymphoid lineages (T cells, B cells, NK cells).
[0151] Induced pluripotent stem cells (iPS cells or iPSCs) are pluripotent stem cells artificially prepared from non-pluripotent cells (usually adult human cells, or terminally differentiated cells, such as fibroblasts, hematopoietic cells, muscle cells, neurons, epidermal cells, etc.) by introducing certain factors (called reprogramming factors).
[0152] Precursor cells or progenitor cells may be genetically modified. In some embodiments, stem cells or progenitor cells express exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) or both. In some embodiments, precursor cells or progenitor cells express exogenous invariant natural killer T cell (iNKT)-associated TCRs. In some embodiments, stem cells or progenitor cells express exogenous antigen-specific TCRs or exogenous genetic modifications of genes regulating differentiation, amplification, or function. In some embodiments, these methods further include genetically modified precursor cells or progenitor cells.
[0153] Reagent test kit
[0154] Kits for synthetic peptides, their protein conjugates, fusion proteins, and combinations thereof, as disclosed herein, are also within the scope of this disclosure.
[0155] For example, a kit may contain one or more reagents or components that are useful, necessary, or sufficient for practicing any of the methods described herein, such as application reagents, cell culture media or components thereof, negative and positive control samples (e.g., cells, template DNA), cells, containers (e.g., cell culture dishes), detection and analysis instruments, software, instructions, etc.
[0156] The kit may include instructions for use for any of the methods described herein. The instructions may include a description of methods for differentiating, stimulating, and / or expanding T cells or NK cells. The instructions typically include effective amounts of the synthetic peptides, protein conjugates, fusion proteins, and compositions disclosed herein, as well as information on the conditions for contacting T cells or NK cells with the disclosed synthetic peptides, protein conjugates, fusion proteins, and compositions. Instructions provided with kits disclosed herein are typically written instructions on a label or packaging insert.
[0157] The kits provided herein are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging, etc. The packaging may be for single use or multiple use. As described above, the kit may optionally provide additional components, such as buffers and explanatory information. Typically, the kit includes a container and a label or one or more packaging inserts on or associated with the container. In some embodiments, this disclosure provides an article of manufacture containing the contents of the aforementioned kit.
[0158] Medicine boxes typically provide their various components within one or more packages (e.g., fiber-based, cardboard, polymer-based, or polystyrene foam-based boxes). The outer shell can be configured to maintain a temperature difference between the interior and exterior, for example, to provide thermal insulation properties, thereby holding the reagent at a preselected temperature for a preselected time. The packaging can be airtight, waterproof (e.g., impermeable to changes in moisture or evaporation), and / or opaque.
[0159] sequence
[0160] The various polypeptides mentioned in this disclosure include the following.
[0161]
[0162]
[0163] The exemplary spacer peptides mentioned in this disclosure include the following.
[0164]
[0165] Example
[0166] The following are embodiments of the present invention and should not be construed as limiting.
[0167] Example 1
[0168] Starting with the IL-2 structure 2B5I, which includes IL-2 that interacts with three receptors (α, β, and γ receptors), the IL-2 structure that interacts with β and γ is maintained while the remainder of this structure is removed. Figure 1A and 1B The pruned version of IL-2 was then fed into a generative diffusion model (RFdiffusion) to generate a backbone of IL-2 with the removed portion. Multiple structures were generated and sequenced for expression in *E. coli*, and purified using an IMAC column.
[0169] Recombinant human interleukin-2 (rhIL-2) production in E. coli requires multiple batches and refolding, introducing time-consuming production steps and requiring validation for each batch. All synthetic IL-2s are produced in high yields, and most products are soluble in E. coli, thus eliminating significant manufacturing time and costs compared to rhIL-2 production.
[0170] Example 2
[0171] Using mammalian display and flow cytometry to screen for the synthesis of IL-2 constructs that bind to IL-2Rβ ( Figure 2 The same method was used to screen synthetic IL-2 constructs with higher activity compared to rhIL-2, targeting IL-2Rβ, IL-2Rα, and IL-2Rγ individually. Figure 3ABG6 variants containing one or more amino acid substitutions at C34, E83, R86, and S90 were prepared. All these ABG6-derived variants showed good expression in *E. coli*, and most products were present in the soluble fraction. Two point mutations in the ABG6 sequence, S90E and R86E, increased IL-2Rβ binding and had increased potency in cell proliferation. Surface plasmon resonance was used to test the binding of two synthetic IL-2 constructs, ABG6-M1 (with an S90E substitution in an ABG6 background) and ABG6-M5 (with C34A, R86E, and S90E substitutions in an ABG6 background), to IL-2Rβ, and they exhibited low nanomolar affinity compared to rhIL-2, which has an affinity of approximately 500 nM. Figure 4 Additionally, no affinity for IL-2Rα could be detected using SPR.
[0172] To test protein function, specifically activation of the STAT5 pathway in YT cells, tumor cell lines exhibiting NK cell-like phenotypes and cytotoxic activity were used. This assay showed lower phosphorylation but stronger activity compared to rhIL-2 when CD25 was knocked out from the genome. Figure 5 Additionally, NK92 cells were activated and exhibited proliferation similar to that of rhIL-2. When IL-2Rα was blocked with an antibody, even greater proliferation was observed. Figure 6 Using the same cells, IFN-γ secretion was monitored, and significantly higher activity was observed with synthetic IL-2 compared to rhIL-2. Figure 7 Increased IFN-γ promotes anti-tumor mechanisms, which in turn facilitates the application of synthetic IL-2 in cell therapy. Most common cell therapies require the expansion of engineered T cells. CD8 and CD4 / CD8 positive T cells were isolated, and their expansion characteristics were compared with rhIL-2. Figure 8 and 9 The phenotypes of stimulated and expanded T cells were tested, and no differences were found in the expression of different T cell phenotypes between rhIL-2 and ABG6-M1. Figure 10 ).
[0173] The synthesized IL-2 peptides also exhibited greater thermostability than rhIL-2. Thermostability was determined by heating 1.5 mL tubes containing 100 µL of IL-2 ABG6-M1 and rhIL-2 at 4 °C or 95 °C for 15 min. Their ability to induce NK92 proliferation was then tested. The ED50 value was determined by calculating the protein concentration at half-maximum proliferation. Dose-response curves were generated by measuring cell proliferation at protein concentrations ranging from 0.015 ng / mL to 30 ng / mL. ABG6-M1 showed no loss of activity, while rhIL-2 lost 60% of its activity (Table 1).
[0174] Table 1:
[0175] The synthetic IL-2 peptide also exhibited greater stability in cell culture medium than rhIL-2. Specific activity was assessed by a proliferation bioassay in NK92 cells, in which cells were treated with specified concentrations of ABG6 M1 or IL-2 for 72 hours. Cell proliferation was measured using a cell counting kit-8 assay (CCK-8; APExBIO). Figure 12A As shown, after incubation at 37°C for 10 days at concentrations of 50 ng / mL, 25 ng / mL, or 10 ng / mL, ABG6-M1 exhibited greater specific activity and was comparable to rhIL-2 at each tested concentration, as well as the control stored at 4°C without any incubation. rhIL-2 showed less than 50% of the specific activity of the control at each concentration. When comparing the stability of 10 ng / mL ABG6-M1 and rhIL-2 over time, the specific activity of ABG6-M1 remained relatively constant and similar to the control for up to two months (Figure 12b). However, the specific activity of rhIL-2 decreased over time, even after 10 days, and was well below 50% of the control. Figure 12A As shown in the figure. This data indicates that the synthetic IL-2 peptide not only possesses thermal stability, but is also particularly suitable for use in bulk culture medium formulations for cell therapy, leading to improved cost efficiency and reduced labor during cell production.
[0176] The scope of this invention is not limited to what has been specifically shown and described above. Those skilled in the art will recognize that suitable alternatives exist for the examples of materials, constructions, structures, and dimensions described. Variations, modifications, and other implementations of the content described herein will be apparent to those skilled in the art without departing from the spirit and scope of the invention.
[0177] Numerous references, including patents and various publications, have been cited and discussed in this specification. These references and discussions are provided solely to clarify the description of the invention and not to acknowledge that any reference is prior art to the invention described herein. All references cited and discussed in this specification are incorporated herein by reference in their entirety.
Claims
1. A synthetic polypeptide that binds to the interleukin-2 receptor subunit β (IL-2Rβ), wherein the synthetic polypeptide comprises: The first domain has the amino acid sequence LQLEHLLLDLQM (SEQ ID NO: 1); A second domain having an amino acid sequence of RDLISNINVI (SEQ ID NO: 2), EDLISNINVI (SEQ ID NO: 3), RDTISNINVI (SEQ ID NO: 4), RDLIENINVI (SEQ ID NO: 5), RDTIENINV (SEQ ID NO: 6), EDLIENINVI (SEQ ID NO: 7), EDTISNINVI (SEQ ID NO: 8), or EDTIENINV (SEQ ID NO: 9); and The third domain having an amino acid sequence of LNRWITFCQ (SEQ ID NO: 10) or LNRWITFAQ (SEQ ID NO: 11).
2. The synthetic polypeptide of claim 1, wherein the synthetic polypeptide has less than 50% identity with SEQ ID NO:
12.
3. The synthetic polypeptide of claim 1 or 2, wherein the first domain, the second domain, and the third domain are present in the synthetic polypeptide in any order from the N-terminus to the C-terminus.
4. The synthetic polypeptide according to any one of claims 1-3, wherein the first domain, the second domain and the third domain are arranged in the synthetic polypeptide in the order from the N-terminus to the C-terminus as: first-second-third or first-third-second.
5. The synthetic polypeptide according to any one of claims 1-4, wherein each domain is separated by spacer polypeptides.
6. The synthetic polypeptide of claim 5, wherein the length of each spacer polypeptide is individually 10 to 60 amino acids.
7. The synthetic polypeptide according to any one of claims 1-6, wherein the synthetic polypeptide comprises one or more additional amino acids at the N-terminus and C-terminus of the first domain, the second domain and the third domain.
8. The synthetic polypeptide according to any one of claims 1-7, wherein the synthetic polypeptide comprises: The first domain has the amino acid sequence LQLEHLLLDLQM (SEQ ID NO: 1); A second domain containing the amino acid sequence RDLISNINVI (SEQ ID NO: 2); and The third domain has the amino acid sequence LNRWITFCQ (SEQ ID NO: 10).
9. The synthetic polypeptide according to any one of claims 1-8, wherein the synthetic polypeptide comprises an amino acid sequence having at least 70% identity with one of SEQ ID NO:13-26.
10. The synthetic polypeptide according to any one of claims 1-9, wherein the synthetic polypeptide comprises the amino acid sequence of any one of SEQ ID NO: 13-26.
11. The synthetic polypeptide according to any one of claims 1-7, wherein the synthetic polypeptide comprises at least one of the following: EDLISNINVI (SEQ ID NO: 3), RDTISNINVI (SEQ ID NO: 4), RDLIENINVI (SEQ ID NO: 5), RDTIENINV (SEQ ID NO: 6), EDLIENINVI (SEQ ID NO: 7), EDTISNINV (SEQ ID NO: 8), and EDTIENINV (SEQ ID NO: 9).
12. The synthetic polypeptide according to any one of claims 1-7 or 11, wherein the synthetic polypeptide comprises one or more amino acid substitutions compared to SEQ ID NO:
18.
13. The synthetic polypeptide of claim 12, wherein, compared with SEQ ID NO: 18, the one or more amino acid substitutions include substitutions of C34, E83, R86, L88, S90, and combinations thereof.
14. The synthetic polypeptide of claim 12 or 13, wherein, compared with SEQ ID NO: 18, the one or more amino acid substitutions include C34A, E83K, R86E, L88T, S90E, and combinations thereof.
15. The synthetic polypeptide of claim 13 or 14, wherein, compared with SEQ ID NO: 18, the synthetic polypeptide further comprises at least one additional amino acid substitution.
16. The synthetic polypeptide of any one of claims 11-15, wherein the synthetic polypeptide comprises an amino acid sequence having at least 70% identity with one of SEQ ID NO:27-33.
17. The synthetic polypeptide according to any one of claims 11-16, wherein the synthetic polypeptide comprises the amino acid sequence of any one of SEQ ID NO:27-33.
18. The synthetic polypeptide according to any one of claims 1-17, wherein the length of the synthetic polypeptide is 90 to 130 amino acids.
19. The synthetic polypeptide according to any one of claims 1-18, wherein the synthetic polypeptide is thermally stable.
20. The synthetic polypeptide according to any one of claims 1-19, wherein the synthetic polypeptide has increased stability in cell culture medium compared with recombinant human IL-2.
21. The synthetic polypeptide according to any one of claims 1-20, wherein the synthetic polypeptide has a completely or partially reduced binding to the interleukin-2 receptor subunit α (IL-2Rα) compared to recombinant human IL-2.
22. A protein conjugate or fusion protein comprising a synthetic polypeptide as described in any one of claims 1-21 linked to at least one portion.
23. The protein conjugate or fusion protein of claim 22, wherein at least one portion is a protein, a protein domain, a polypeptide, or a peptide.
24. The protein conjugate or fusion protein of claim 22 or 23, wherein at least one portion comprises an antibody or a fragment thereof.
25. The protein conjugate or fusion protein of claim 22, wherein at least one portion is polyethylene glycol (PEG).
26. A composition comprising a synthetic polypeptide or a protein conjugate or fusion protein as described in any one of claims 1-21, and a carrier.
27. The composition of claim 26, wherein the composition is a cell culture medium or a component thereof.
28. A method for differentiating, stimulating, and / or expanding T cells or NK cells in vitro or in vitro, the method comprising contacting T cells, NK cells, or their precursor or progenitor cells with a synthetic polypeptide, its protein conjugate or fusion protein, or a composition comprising the like as described in any one of claims 1-21.
Citation Information
Patent Citations
Recombinant immunoglobin preparations
US4816567A
Uncharged morpholino-based polymers having achiral intersubunit linkages
US5034506A
Antibodies that bind human interleukin-18 and methods of making and using
WO2001058956A2
